Abstract: CD44 plays an important role in leukocyte extravasation, which is fortified in autoimmune diseases and delayed-type hypersensitivity (DTH) reactions. There is additional evidence that distinct CD44 isoforms interfere with the extravasation of selective leukocyte subsets. We wanted to explore this question in alopecia areata (AA), a hair-follicle centric autoimmune disease, and in a chronic eczema. The question became of interest because AA is treated efficiently by topical application of a contact sensitizer, such that a mild DTH reaction is maintained persistently. Aiming to support the therapeutic efficacy of a chronic eczema in AA by anti-CD44 treatment, it became essential to control whether a blockade of migration, preferentially of AA effector cells, could be achieved by CD44 isoform-specific antibodies. Anti-panCD44 and anti-CD44 variant 10 isoform ( 
INTRODUCTION
Alopecia areata (AA) is an autoimmune disease of the skin, which affects anagen-stage hair follicles [1, 2] . Extensive AA is often treated by local application of a contact sensitizer, which induces a mild, chronic eczema [3] [4] [5] . Hair regrowth is observed in 50 -70% of patients after 2-6 months [4] . Some C3H/HeJ mice spontaneously develop AA, which closely resembles the human disease. AA can also be transferred to nonaffected littermates using full-thickness skin grafts [6, 7] . As in humans, AA of C3H/HeJ mice can be treated by repeated application of the contact sensitizer squaric acid dibutyl ester (SADBE), and hair regrowth is apparent after 6 -10 weeks [8, 9] . There is evidence that the curative effect of a chronic contact eczema in AA relies on impaired T cell activation as a result of hindrance in APC migration toward the draining lymph node (LN); however, T cell extravasation was not affected [10] . Because of the latter and also as allergen treatment is long-lasting and not always successful, we speculated that a blockade of leukocyte extravasation might provide an additive, therapeutic benefit. We focused on a blockade of CD44, as we demonstrated recently that AA induction can be prevented by treatment with a CD44 variant 10 isoform (CD44v10)-specific antibody [11] . However, anti-panCD44 and anti-CD44v10 have also been shown to interfere with the severity of delayed-type hypersensitivity (DTH) reactions [12] . Thus, the possibility arose that during AA treatment with a contact sensitizer, a blockade of CD44 might affect the (curative) DTH reaction, which would rather promote than inhibit AA progression. Therefore, it became important to explore the mechanisms, whereby anti-CD44 interferes with AA and DTH induction, whether these mechanisms are alike or distinct and whether a blockade of CD44/leukocyte extravasation could be directed selectively toward AA effector cells.
There is ample evidence that CD44, originally described as a leukocyte-homing receptor [13] , plays an important role in the extravasation of T cells [14, 15] as well as monocytes [16, 17] . Earlier studies demonstrated that anti-CD44 inhibits induction of a DTH reaction during the first 24 h, and homing into LN is not affected, indicating that CD44 is required for extravasation [18] . The fact that leukocyte entry into inflamed tissue is impaired in mice with a targeted deletion of CD44 is in line with this assumption [19] .
Several mechanisms have been discussed, whereby a blockade of CD44 could interfere with leukocyte extravasation. First, CD44 has been defined as the major hyaluronic acid (HA) receptor [20] . HA binding, which requires CD44 to be activated [21] [22] [23] [24] , is obviously of utmost importance for the involvement of CD44 in leukocyte migration [25] . In fact, in chronic inflammation, T cell rolling is up-regulated, and the percentage of T cells expressing activated CD44 is increased [26] . The inflammatory cytokines TNF-␣, IL-1␤, as well as LPS induce HA and CD44 expression on endothelial cells [16, 27, 28] , where HA is anchored via CD44. Thus, a positive loop is created, which supports leukocyte rolling further. Moreover, by a direct interaction between CD44 and CD49d, CD44 is involved in firm adhesion [29] .
Second, CD44 can act as a chemokine receptor. It was shown that the hematopoietic [CD44 standard isoform (CD44s)] or CD44v acts as a receptor for osteopontin (OPN) [30, 31] . The C-terminal region of OPN, in particular, interacts with CD44 and induces chemotaxis, and the N terminus interacts with ␤3 integrins and induces spreading and activation [32] . Migration of Langerhans cells into the draining LN during initiation of a contact hypersensitivity reaction also depends essentially on OPN and its interaction with CD44 [33] . In addition, a motile phenotype can be acquired by an intracellular OPN-CD44 association [34] , which is accompanied by colocalization of the complex with ezrin at the leading edge of the migrating cell [35] . Other chemokines, such as CCL5, also associate with CD44 [36, 37] . The CCL5-CD44 complex supports formation of a signaling complex, which initiates p44/42 MAPK activation [36] .
Third, CD44 can initiate signal transduction by itself or as an accessory molecule in concert with the TCR-CD3 complex [38, 39] . It is notable too that the association of CD44 with CD49d does not only promote leukocyte adhesion [29] but also allows CD44 to make use of CD49d-associated, signal-transducing molecules and vice versa [40] .
To evaluate whether a blockade of CD44 could provide an additive, therapeutic benefit in allergen-treated AA, it became essential to know which of the outlined, functional activities are dominating in AA and DTH reactions. Our data indicate that anti-CD44v10 interferes predominantly with macrophages (M) but also with T cell homing into the skin of AA and allergen-treated AA mice, and anti-panCD44 hampers, in addition, T cell homing into the draining LN. Furthermore, activated CD44/CD44v10 associates rather selectively with CD11b (M) and CD49d (T cells)-associations, which are of functional importance.
MATERIALS AND METHODS

Mice
C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, ME, USA) received autoclaved food pellets and acidified water ad libitum. AA was induced by grafting skin (1 cm 2 ) from spontaneously AA-affected mice to normal-haired recipients [6] . Over 90% of grafted mice developed AA within 6 -8 weeks after grafting. Only mice with extensive hair loss were included. Mice were sensitized on a 1-cm 2 area of the back (outside the grafted area) with 2% SADBE in acetone, followed by weekly, topical applications of 0.5% or 1% SADBE in acetone on the entire back. The concentration and total volume of the contact allergen were chosen individually such that a moderately severe contact dermatitis, lasting for 2-3 days, was induced. Where indicated, mice received i.v. antibody injections (150 g) two times weekly, starting at the first challenge with SADBE and concomitantly in control and AA mice. Previous studies revealed that SADBE-induced changes in leukocyte subpopulations, activation marker, and adhesion molecule expression had developed fully at 3 days after treatment-the effect being most pronounced after the third challenge. At this time, hair regrowth had not yet started (data not shown). Therefore, the impact of anti-CD44 treatment was evaluated 3 days after the third SADBE challenge. All ex vivo analyses were performed simultaneously in the four groups of diseased and control mice. The local government authorities approved all animal experiments.
Tissue preparation
Mice were killed by cervical dislocation. Skin, spleen, and draining LN were collected. Dorsal skin samples were embedded in OCT compound (Tissue Tek, Sakura, Zoeterwoude, Netherlands) and snap-frozen in liquid nitrogen. For the isolation of cutaneous leukocytes [skin-infiltrating leukocytes (SkIL)], fat and s.c. muscle tissue were removed. Skin was layered epidermis-uppermost on sterile gauze and incubated three times for 30 min with a 1-mg/ml trypsin/ EDTA solution. After each incubation, the skin was pressed against the sterile gauze, and isolated cells were collected in RPMI 1640/10% FCS. After the final trypsin treatment, cells were pooled, washed, and resuspended in RPMI-1640/10% FCS and 10 Ϫ3 M HEPES buffer and incubated at 37°C for 2 h for the recovery of cell surface molecule expression. For flow cytometry analysis, SkIL from three animals were pooled. Single cell suspensions from skindraining LN and the spleen cells (SC) were prepared by pressing through fine gauze. Viability was determined by Trypan blue exclusion (SkIL: Ͼ70%; LN cells, SC: Ͼ95%). Where indicated, CD4 ϩ or CD11b ϩ cells were enriched from LN or SC by magnetic bead sorting (Miltenyi, Mönchengladbach, Germany).
Cell lines and antibodies
The endothelial cell line C166 [41] was maintained in DMEM/10% FCS. For functional studies, the panCD44-specific antibody IM7 [42] and the CD44v10-specific antibody K926 [12] were used. Both antibodies do not interfere with HA binding [12, 43] . The CD44v10-specific antibody K926 derives from a fusion of rat SC with Ag8 after vaccination with a CD44v4-v10-GST fusion protein. By peptide competition, the epitope could be restricted to AA 583-606, where only AA 594 differs between rat and mouse [12] . The following additional primary antibodies were used: antimouse CD4 (YTA3.2.1), CD8 (YTS169.4.2.1), CD11a (M17.5.2), CD11b (YBM6.6.10), CD54 (YN1/1.7.4; European Animal Cell Culture Collection, Porton Down, UK); antimouse CD25 (7D4), anti-panCD44 (KM81; American Type Culture Collection, Manassus, VA, USA); anti-CD49d (PS/2; kindly provided by Kaotu Miyazaki, Saga Medical School, Saga, Japan) [44] ; antimouse CD11c (HL3), CD28 (37.51), CD40 (3/23), CD49f (GOH3; antihuman, cross-reacts with mouse), CD80 (1G10), CD86 (GL1), CD95 (Jo2), CD95L (MFL3), CD102 (3C4), CD152 (9H10), CD154 (MR1), CCL2/MCP-1 (2H5; BD PharMingen, Heidelberg, Germany); CCL1/TCA3 (polyclonal), CCL17/thymus and activation-regulated chemokine (monoclonal), CCL20/MIP-3␣ (monoclonal), CCR6 (monoclonal; R&D, Wiesbaden, Germany); CCL5/RANTES (polyclonal), CXCL10 (polyclonal; Biotrend, Köln, Germany); OPN (polyclonal; Assay Designs, Ann Arbor, MI, USA); CCR4 (polyclonal), CCR8 (polyclonal; Abcam Ltd., Cambridgeshire, UK). Secondary reagents were FITC-, PE-, or allophycocyaninlabeled antirat IgG, antirat IgM, antirabbit IgG, antihamster IgG, or streptavidin (Strep; Dianova, Hamburg, Germany; Becton Dickinson, Heidelberg, Germany; or Biotrend, Köln, Germany).
Flow cytometry
Flow cytometry followed routine procedures. For intracellular staining, cells were fixed and permeabilized in advance. Flow cytometry was evaluated using a FACSCalibur (Becton Dickinson). Contaminating keratinocytes in SkIL preparations were excluded by gating. Analysis was performed by the Cell Quest program. Experiments were repeated at least three times. Values represent the mean and SD. Significance of differences was evaluated using the two-tailed Student's t test.
Immunohistology
Sections (5 m) of snap-frozen skin were fixed (chloroform/acetone, 1:1, 4 min) and treated with levamisole to ablate tissue alkaline phosphatase activity. Nonspecific binding was blocked using an avidin-biotin-blocking kit (Vector Laboratories, Burlingame, CA, USA), and 2% normal serum was derived from the same species as the secondary antibodies. For chemokine staining, tissues were fixed in paraformaldehyde (4%) and permeabilized (0.1% Triton X-100, 4 min, 4°C). Tissues were incubated for 1 h with the primary antibody, washed, and exposed to biotinylated secondary antibodies (30 min) and an alkaline phosphatase-conjugated, avidin-biotin complex (5-20 min). Tissue sections were counterstained with Mayer's hematoxylin. Primary antibodies were replaced with normal rat or rabbit IgG for negative controls.
ELISA
Standard ELISA procedures were used. Plates were coated with anti-CD44 (Clone KM81). Plates were washed, blocked (100 g/ml BSA), and incubated overnight with 50 l mouse serum (dilution 1:50 -1:800). After washing, 50 l biotinylated anti-CD44 (Clone IM7) was added (1 h, room temperature). After washing, alkaline phosphatase-coupled Strep and substrate (p-nitrophenyl phosphate) were added. Absorbance was read at 405 nm. Assays were run in triplicates.
Immunoprecipitation (IP) and Western blot (WB)
SC were lysed (30 min, 4°C) in HEPES buffer (25 mM HEPES, 150 mM NaCl, pH 7.4) containing 1% CHAPS, 1 mM PMSF, 1 mM NaVO4, 10 mM NaF, and a protease inhibitor mix (Boehringer Mannheim, Germany). Lysates were centrifuged (13,000 g, 10 min, 4°C) and used for IP (1 h, 4°C) followed by incubation with Protein G sepharose (1 h). Immune complexes were washed four times with lysis buffer, dissolved in Laemmli buffer, and resolved by SDS-PAGE. Samples were resolved on 8% SDS-PAGE, and proteins were transferred to nitrocellulose membrane (Amersham, UK; 30 V, 16 h, 4°C). Membranes were blocked (PBS/5% BSA/0.1% Tween-20, 1 h, room temperature) and blotted with primary antibodies, followed by HRP-conjugated secondary antibodies or Strep (1 h, room temperature). Blots were developed with the ECL detection system.
In vitro leukocyte migration
Draining LN cells (5ϫ10 4 ) were seeded in the upper part of a Boyden chamber in 30 l RPMI/0.1% BSA. Where indicated, cells had been loaded with antibody before seeding (10 g/ml, 30 min, 4°C). Cells were washed and seeded as above. The lower chamber, separated by a 5-m pore-size polycarbonate membrane (Neuroprobe, Gaithersburg, MD, USA) contained 30 l RPMI/0.1% BSA plus 40 ng/ml OPN (R&D). The concentrations of OPN for optimal response were determined beforehand. After incubation (4 h), cells in the lower chamber were counted. Transendothelial cell migration was evaluated after seeding C166 cells on 3 m polycarbonate tissue-culture inserts (Nunc, Roskilde, Denmark). After overnight culture to form a monolayer, OPN (40 ng/ml) was added to the lower chamber, and LN cells (2ϫ10 5 ) were added to the upper chamber. Where indicated, C166 cells were activated by incubation with 10 ng/ml TNF-␣ for 4 h, or C166 cells were incubated with anti-CD44 (10 g/ml, 30 min, 4°C). In some experiments, LN cells were preincubated with anti-CD44 as described above. Transendothelial cell migration was evaluated after 12 h. Assays were run in triplicates. Cell migration is presented as percentage of migrating cells taking the starting load as 100%.
Cell transfer and migration
Single LN cell suspensions from pooled, skin-draining LN were labeled with CFSE. Mice received an i.v. injection of 1 ϫ 10 7 CFSE-labeled leukocytes concomitantly with 150 g antibody. Mice were killed 3 days after treatment.
Statistics
Significance was evaluated by the two-tailed Student's t test for unequal variance or by the two-tailed Wilcoxon rank sum test.
RESULTS
The experimental model
There is strong evidence that CD44 plays an important role in leukocyte extravasation. This is true for activated leukocytes in autoimmune disease as well as in allergic reactions [26, 45] . It has not yet been explored whether a blockade of CD44 affects the same or different effector cells in autoimmune and allergic reactions, whether different CD44 isoforms are involved, and whether organ-related differences exist. AA can be treated by a chronic allergic eczema. Thus, allergen-treated AA mice in comparison with control, AA, or allergen-treated mice appeared to provide a suitable model to answer these questions. From a clinical point of view, we anticipated that an analysis of the three groups of diseased mice could provide additional information. We assumed that according to disease-related additive or selective effects of CD44 in leukocyte migration, a CD44 blockade might serve as a supporting therapeutic in allergen-treated AA. As previous work provided evidence that CD44v10 expression is particularly altered in skin-associated immune diseases [46] , we concomitantly evaluated the effect of anti-CD44v10. Starting contemporarily with the first challenge in DTH and AA/DTH mice, mice received 5 ϫ 150 g antibody i.v.
Anti-CD44v10 and anti-panCD44 interfere distinctly with leukocyte migration
Skin-draining LN cells from AA mice display high migratory activity in vitro, even in the absence of any stimulus, whereas 3 Fig. 1 . Impact of anti-panCD44 and anti-CD44v10 on migration of skin-draining LN cells (LNC), which (A) from untreated and SADBE-treated control and AA mice, killed 3 days after the third challenge, were incubated with control IgG, anti-panCD44, or anti-CD44v10 (10 g/ml, 30 min, 4°C), washed, and seeded in the upper part of a Boyden chamber. The lower part contained RPMI/0.1% BSA or in addition, 40 ng/ml OPN. After 4 h (37°C, 5% CO 2 ), cells in the lower chamber were counted. (B) Control, SADBE-treated, AA, and SADBE-treated AA mice received control IgG, anti-panCD44, or anti-CD44v10 for 2 weeks (150 g per mouse, i.v., twice per week). Three days after the third challenge with SADBE, mice were killed, LN were excised, and LN cells were treated as described in A. LN cells from control and allergen-treated mice migrated mostly in response to OPN or CXCL10 [10] . Thus, it became of interest to see whether anti-CD44 would hamper spontaneously migrating AA leukocytes similar to leukocytes from control and DTH mice and whether anti-CD44 would also be effective in the combined disease state. Indeed, irrespective of the abovementioned, disease-associated differences, in vitro migration of draining LN cells of untreated and allergen-treated control and AA mice was inhibited significantly after LN cells had been preincubated with anti-panCD44 or anti-CD44v10. Although migration in the absence of an external stimulus was inhibited equally by anti-panCD44 and anti-CD44v10, migration of AA LN cells in response to OPN was inhibited more strongly by anti-CD44v10 than anti-panCD44 (Fig. 1A) .
It is important that in vivo treatment with anti-panCD44 or anti-CD44v10 also sufficed for a significant reduction in draining LN cell migratory activity. Migration was inhibited to a comparable degree when mice had received anti-panCD44 or anti-CD44v10. Reloading the LN cells ex vivo with antipanCD44 or anti-CD44v10 treatment strengthened the inhibitory effect of in vivo anti-CD44 treatment. With minor differences, this was true for all four groups of mice (Fig. 1B) .
To explore the impact of anti-CD44 on leukocyte migration in vivo, we evaluated the overall recovery of leukocytes first. As shown before [9] , higher numbers of draining LN cells and SkIL were recovered from AA and allergen-treated mice. It is interesting that the recovery of draining LN cells was decreased only in anti-panCD44-but not in antiCD44v10-treated mice and only in diseased animals. The overall recovery of SkIL was reduced slightly in all four groups of anti-panCD44-and anti-CD44v10-treated mice. The effect was slightly stronger in diseased rather than healthy mice (Fig. 1C) .
To confirm that only anti-panCD44 interferes with LN homing, and anti-panCD44 as well as anti-CD44v10 interfere with skin homing, mice received an i.v. injection of CFSE-labeled LN cells, which were derived from mice with corresponding health status; i.e., AA mice received LN cells from AA mice. Three days later, the recovery of dye-labeled cells was evaluated in skin-draining LN and the skin (an example is given in Fig. 1D ). LN cells from diseased mice homed more readily into the skin than LN cells of control mice. This was confirmed by a criss-cross transfer (control LN cells into AA or DTH mice and vice versa; data not shown). It is notable that in vivo migration toward the skin was inhibited by anti-panCD44 and anti-CD44v10. Only anti-panCD44, but not anti-CD44v10, inhibited the entry into LN of diseased mice. In the few dye-labeled cells recovered in LN of anti-panCD44-treated mice, CFSE intensity was high. Instead, in control IgG-or anti-CD44v10-treated mice, the intensity of the CFSE label ranged from 10 2 to 10 4 (Fig. 1E ). This could be indicative for anti-panCD44, inhibiting not only leukocyte migration but also leukocyte proliferation. A time-course analysis, where recovery of CFSE-labeled cells was recorded between 1 and 5 days after application (data not shown), supported this suggestion.
Taken together, anti-CD44 treatment exerted a strong effect on leukocyte migration in vitro and a distinct effect on leukocyte migration in vivo. As anti-CD44v10 inhibited skin but not LN homing, the question arose whether distinct CD44 isoforms
Anti-panCD44 and anti-CD44v10 block skin homing of T cells and monocytes
Particularly in the skin, the composition of the major leukocyte subpopulations differs among control, AA, and DTH mice with a preponderance of T cells in AA and M in DTH (Fig. 2, A  and B) . Therefore, we compared the impact of anti-CD44 treatment on the total number of T cells and M rather than on the relative percentage. Anti-CD44 treatment had only a minor effect on the overall number of CD4 ϩ and CD8 ϩ cells in draining LN of all four groups of mice (data not shown). However, the number of freshly activated CD69 ϩ and CD154 ϩ T cells was reduced significantly in diseased mice (Fig. 2C) . In the skin, the effect of anti-CD44 treatment varied depending on the disease. In AA mice, CD4 ϩ and CD8 ϩ SkIL and in allergen-treated mice, CD11b
ϩ SkIL were more strongly reduced. In AA/DTH mice, the number of CD4 ϩ , CD8 ϩ , and CD11b
ϩ SkIL was reduced to a comparable degree (Fig. 2D ). Considering T cell extravasation, anti-panCD44 and antiCD44v10 particularly inhibited extravasation of freshly activated T cells (Fig. 2E) . The finding was confirmed in vitro.
Migration of CD4
ϩ cells was inhibited most strongly by antipanCD44 in AA and AA/DTH. Monocyte migration was inhibited by anti-panCD44 and slightly more efficiently by antiCD44v10 (Fig. 2F) .
Taken together, anti-panCD44 and anti-CD44v10 interfere with T cell and M extravasation into the skin, such that depending on the disease, the dominating effector cell subpopulation-monocytes in contact allergy and CD4 ϩ cells in AA-becomes affected most strongly. Inhibition of T cell extravasation preferentially affects activated T cells. Homing into the draining LN is only blocked by anti-panCD44 and mostly, affects T cells. According to these disease-and CD44 isoform-specific effects, it became of interest to elucidate the mechanism(s), whereby a blockade of CD44/ CD44v10 interferes with leukocyte migration. We asked four questions: Will the treatment influence CD44 expression? Are chemokines of major importance? Are CD44-associating, adhesion molecules involved? What is the contribution of endothelial cells?
Anti-CD44 does not influence CD44 expression CD44 is supposed to support leukocyte rolling by binding to HA on endothelial cells, a process assisted further by upregulated CD44 expression on vessel endothelium, which retains HA [43] [44] [45] . However, neither K926 (anti-CD44v10) nor IM7 (anti-panCD44) occupies the HA-binding site. Accordingly, these antibodies did not compete with binding of FITClabeled HA to activated T cells (data not shown). Alternatively, anti-CD44 could interfere with leukocyte egress by inducing internalization or shedding of CD44.
CD44 expression was not modulated in LN cells and SkIL of anti-CD44-treated AA or DTH mice. Solely, in control mice, anti-CD44v10 treatment was accompanied consistently by a slight reduction in CD44v10 expression (Fig. 3, A-C) . There was also no evidence for an antibody-induced, pronounced shedding of CD44. Sera were collected 3 days after the last antibody treatment and were tested for the presence of CD44 by a sandwich ELISA. The relative amount of soluble CD44 in the sera was not increased in anti-CD44-treated healthy or diseased mice. These findings argue against a loss of CD44 being responsible for the reduced migratory activity (Fig. 3D) .
The impact of anti-CD44 on chemokine and chemokine receptor expression CD44 is a receptor for several chemokines and can form complexes with chemokines and chemokine receptors [30, 31, 36, 37, 47, 48] . In addition, chemokine expression is strongly up-regulated in the dermis of contact allergen-treated and although less pronounced, AA mice [10] . Thus, the anti-CD44- ϩ and CD11b ϩ LN cells of control and diseased mice were incubated with the indicated antibodies. Migration in response to OPN was evaluated as described in Figure 1A . *, Significant differences (PϽ0.01) in comparison with mice receiving a control IgG. mediated blockade of leukocyte migration could be supported by hindrance in chemokine binding or by modulation of chemokine or chemokine receptor expression.
We first evaluated chemokine receptor expression and coexpression with CD44 in LN cells and SkIL of untreated and allergen-treated, control and AA mice. A representative example is shown in Figure 4A . CCR6 expression was high in LN cells and SkIL of C3H/HeJ mice and was increased further in diseased mice. CCR4 and CCR8 expression was also upregulated in LN cells and SkIL of diseased mice. In all four groups of mice, CCR4 ϩ , CCR6 ϩ , and CCR8 ϩ LN cells and SkIL coexpressed mostly CD44. Coexpression was increased further in SkIL of diseased mice (Fig. 4A) . It is important that anti-panCD44 treatment was accompanied consistently by upregulated CCR6, CCR4, and CCR8 expression, exclusively in AA/DTH LN cells (Fig. 4B) but not in SkIL (data not shown).
Changes could have been expected in chemokine expression to correlate with those in chemokine receptor expression. However, this was not obvious in all instances. Thus, anti-panCD44 had no impact on chemokine expression in SkIL and LN cells (data not shown). Also, anti-CD44v10 induced only a slight reduction of CCL20 ϩ [CCR6 ligand, dendritic cell (DC), and T cell recruitment] in AA SkIL and CCL17 (CCR4 ligand and T cell recruitment) and CCL1 (CCR8 ligand and monocyte recruitment) in allergen-treated SkIL. Expression of OPN, CCL2, CCL5, and CXCL10 was unaltered (data not shown). However, CCL2 (MCP-1 and leukocyte recruitment in general) expression was strongly and CCL17 expression distinctly reduced in the dermis of anti-CD44-treated DTH and AA/DTH mice (Fig.  5) . Expression of the CD44 ligand OPN was reduced mainly in anti-CD44v10-treated AA mice (data not shown).
Thus, anti-panCD44 affected the recovery of chemokine receptor expression only in AA/DTH LN cells. The increased percentage of chemokine receptor-expressing LN cells but not SkIL argues for an active retention in the draining node. Chemokine expression was reduced more strongly in the dermis rather than in SkIL and not in LN cells.
Does anti-CD44 hamper adhesion via CD44-associated molecules?
Activated CD44 can cooperate with CD49d to promote firm adhesion in inflammatory diseases [29, 47] . We demonstrated recently that this also accounts for AA [40] . Thus, we first asked whether coexpression of CD44 and CD49d would also be strengthened in allergen-treated mice. Coexpression of CD44 with CD11b, CD49d, and CD54 was high in unseparated LN cells of all four groups of mice, and coexpression of CD44 and CD49d was strengthened in LN cells of diseased mice (data not shown). The same accounted for coexpression of CD44 with CD49d or CD54 in SkIL of the three groups of diseased mice. Coexpression with CD11b was only strengthened in unseparated SkIL of allergen-treated mice (Fig. 6, A and B) . Coimmunoprecipitation of SC lysates revealed that the increase in coexpression correlates with associations of these molecules. CD44 coimmunoprecipitates with CD54 in SC from healthy and diseased mice, but coimmunoprecipitation is increased significantly in diseased mice. An association among CD44 and CD11a, CD11b, and CD49d was only observed in SC of diseased mice and was most pronounced in AA/DTH. It is notable that CD44v10 only associated with CD11b and only in diseased mice. An additional, weak association of CD44v10 with CD11a was observed consistently in AA/DTH (Fig. 6C) .
As revealed by antibody-blocking studies, these associations of CD44 with integrins and CAMs have bearing on leukocyte migration. Anti-CD11a, -CD11b, -CD49d, and -CD54 inhibited LN cell migration only in diseased mice, and the degree of inhibition correlated well with the degree of association between the respective molecules and CD44. (Fig. 6D) . To see whether the blockade by the integrin-specific antibodies is restricted to leukocyte subpopulations, CD4
ϩ and CD11b ϩ cells were separated. In fact, anti-CD49d preferentially inhibited CD4 (Fig. 6E) .
Taken together, "activated" CD44 associates with additional adhesion molecules, such as CD49d, CD11b, and CD54. Accordingly, an anti-CD44 blockade could well-inhibit adhesion and migration of activated T cells and M via these associated molecules.
A blockade of CD44 on vascular endothelium can contribute to impaired leukocyte migration
Inflammation is accompanied by up-regulated CD44 expression on endothelial cells, which serves to harbor HA and chemokines to attract and capture leukocytes [49, 50] . Thus, the effect of an in vivo anti-CD44 treatment on leukocyte migration in AA and DTH also could have been supported by a blockade of CD44 on endothelial cells.
We first evaluated panCD44 and CD44v10 expression on dermal vascular endothelium and on high endothelial venules of LN. CD44v10 expression was seen on dermal vascular endothelium, and expression was strong in diseased mice. panCD44 expression apparently was up-regulated in high endothelial venules of draining LN of diseased mice (Fig. 7A) . However, CD44v10 was hardly expressed (data not shown). To further evaluate a possible impact of anti-CD44 treatment on leukocyte migration via a blockade of CD44 on endothelial cells, we made use of an endothelial cell line [44] , which expresses CD44 and CD44v10 at a high level (Fig. 7B) . Transmigration of leukocytes seeded on an endothelial cell mono- (Fig. 7C) . When endothelial cells were preincubated with anti-panCD44 or anti-CD44v10 before addition of LN cells, transmigration was inhibited, although to a lesser degree than by preincubation of LN cells with anti-CD44. Furthermore, anti-CD44-mediated inhibition of transmigration was not strengthened by endothelial cell activation. Finally, transmigration of LN cells from AA and AA/DTH mice was even less impaired by a blockade of endothelial cell CD44 than transmigration of LN cells from healthy mice (Fig. 7D) .
As dermal vascular endothelial cells strongly express CD44v10, the selective inhibition of skin homing could rely partly on a CD44v10 blockade on endothelial cells. Conversely, leukocyte migration was less inhibited by an endothelial cell than by a leukocyte CD44 blockade and was weakest by a CD44 blockade on activated endothelial cells. Although these findings require further analyses of the CD44-mediated crosstalk between endothelial cells and leukocytes, with respect to the effect of anti-CD44 on leukocyte migration in AA and DTH, leukocytes are obviously the major antibody target.
DISCUSSION
CD44 plays a major role in leukocyte extravasation in autoimmune disease and allergic reactions [25, 51] . It has not yet been explored whether distinct CD44 isoforms are involved, whether there are organ-related differences, and whether an antibody-mediated blockade of CD44 affects distinct leukocyte subpopulations. AA is an autoimmune disease [1, 2, 52], which can be treated efficiently by induction of a mild, chronic allergic eczema [4, 5] . It is interesting that induction of AA in C3H/HeJ mice can be prevented by repeated injections of anti-CD44v10 [11] , and anti-CD44v10 suffices to delay the onset of Th1-based DTH reactions [12] . As autoimmune diseases require a persisting recruitment of effector T cells [53] , and DTH reactions are characterized by an early influx of inflammatory cells, followed by Th1 cells, which sustain M activation [54] , a comparative evaluation of the impact of anti-CD44 on leukocyte migration in a fully developed autoimmune disease and a superimposed, persisting allergic DTH reaction appeared well-suited to answer the questions of a potential organ and effector cell (T cells vs. monocytes) specificity of the CD44 involvement in leukocyte extravasation.
What are the targets of anti-CD44?
Endothelial cells as well as leukocytes express CD44, and a blockade at both levels could contribute to impaired leukocyte migration. This, apparently, is the case, but the endothelial cells' contribution is minor.
Endothelial cells contribute to leukocyte adhesion via upregulated CD44 expression, HA secretion, and chemokine binding [16, 27, 28, 49] . In fact, in vitro studies provided evidence for a reduction in transendothelial lymphocyte migration by a CD44 blockade on endothelial cells. However, the blockade of transendothelial cell migration did not vary in ϩ LN cells, and CD11b ϩ SC of mice, as described above, were preincubated with anti-CD11a, -CD11b, -CD49d, and -CD54 (10 g/ml, 30 min, 4°C), washed, and seeded in the upper part of a Boyden chamber. The lower part contained RPMI/0.1% BSA and 40 ng/ml OPN. After 4 h (37°C, 5% CO 2 ), cells in the lower chamber were counted. *, Significant differences (PϽ0.01) in comparison with cells incubated with control IgG. dependence on the endothelial cells' activation state and was much weaker than inhibition of migration by a blockade of CD44 on leukocytes. Thus, a blockade of CD44 on endothelial cells can contribute to the inhibition of leukocyte extravasation, but the different efficacy of an anti-CD44 blockade in diseased as compared with healthy mice apparently relies predominantly on the leukocyte.
CD44-mediated leukocyte rolling on hyaluronan secreted by endothelial cells [51, 55] depends on the activation state of CD44 [21] [22] [23] [24] and should be enhanced in inflammation [26] . Our results are in line with this observation, taking into account that anti-CD44-mediated inhibition was strengthened significantly in diseased as compared with healthy mice and that anti-CD44-mediated inhibition of T cell extravasation preferentially affected activated (CD69 ϩ , CD154 ϩ ) T cells. Also, a CD154-CD40 interaction early during induction of response induces strong up-regulation of CD44 on T cells [56] . These strongly CD44-positive cells may be prone for targeting by anti-CD44, which interferes with their extravasation.
CD44 is also involved in M migration [16, 17, 28] . As AA is a T cell-mediated, autoimmune disease [52, 57] , and M are the primary effectors in DTH reactions [54] , it became of special interest whether in allergen-treated AA mice, a blockade of CD44 affects T cell as well as M migration. As suggested by the reduction of CD11b ϩ SkIL in anti-CD44-treated mice and demonstrated by the in vitro inhibition of monocyte migration, anti-CD44, indeed, inhibits monocyte recruitment toward the skin in healthy and diseased mice. It is notable that although T cell migration was inhibited more strongly by anti-panCD44 than by anti-CD44v10, M recruitment was inhibited most strikingly by anti-CD44v10.
The finding that anti-panCD44/anti-CD44v10 inhibits skin homing of T cells and monocytes explains the efficacy of anti-CD44 in a skin-associated, T cell-mediated autoimmune disease and a chronic DTH reaction.
The organ selectivity of the anti-CD44-mediated blockade in leukocyte migration Anti-panCD44 and anti-CD44v10 interfere with leukocyte extravasation into the skin. Anti-panCD44 but not anti-CD44v10 also interfered with T cell homing into LN. This organ selectivity of a CD44 isoform-specific blockade of leukocyte migra- tion is by no means restricted to the model described; e.g., neither anti-CD44v10 nor anti-panCD44 interferes with leukocyte homing into inflamed gut mucosa (M. Zöller, unpublished finding).
The selective interference of anti-CD44v10 with skin homing corresponds to the predominant CD44v10 expression in malignant and reactive human skin lymphocytes [12, 58, 59] and as shown here, in dermal endothelial cells. CD44v10 expression mainly in M (and a subpopulation of CD8 ϩ T cells) [12] may well contribute to the strong effect of antiCD44v10 on leukocyte skin homing in mice suffering with a chronic DTH reaction. Finally, in vitro and in vivo, antiCD44v10 inhibited migration in response to OPN more strongly than anti-panCD44. A lower in vivo efficacy of antipanCD44 may be a consequence of the rather ubiquitous expression of CD44s [60] and accordingly, an insufficient amount of antibody. However, in in vitro studies, cells were incubated with an excess of antibody. Taking into account that OPN binds particularly CD44v [30, 31] , we hypothesize that OPN-binding CD44 isoforms likely include the v10 exon product. A blockade of CD44v10 as a selective chemokine ligand could add further to the organ selectivity of CD44-mediated leukocyte extravasation. Finally, in activated leukocytes, CD44v10 can associate with CD11b. The association with an integrin expressed mostly on M could well-strengthen the efficacy of anti-CD44v10 in mitigating DTH reactions.
The organ selectivity of distinct CD44 isoforms in leukocyte extravasation may provide a way out of severe side-effects encountered frequently in therapeutic settings using anti-pan CD44 [61] .
The molecular mechanisms accounting for the anti-CD44-mediated blockade in leukocyte extravasation
The question about the mechanism(s), whereby anti-CD44 blocks leukocyte extravasation, could not yet be answered fully. However, our data provided hints toward potential molecular pathways: The anti-panCD44 (IM7) [43] , and the antiCD44v10 (K926) [12] antibodies do not interfere with HA binding. This excludes the most straight-forward explanation that leukocyte binding to endothelial cell-bound HA may be hampered [47, 51] .
Second, anti-CD44 does not modulate CD44 expression. A reduction in CD44 expression by antibody-initiated shedding has been demonstrated for IM7 in rheumatoid arthritis (RA) [62, 63] . However, CD44 surface expression was hardly reduced in antibody-treated mice, and there was no evidence for antibody-induced, pronounced shedding. The different effect of IM7 on CD44 shedding in RA and our models could be a result of the chronic nature of AA, the repeated allergen treatment, and our long-lasting antibody treatment, such that a new balance between increased shedding and synthesis could have become established, which might hide an immediate effect of IM7 on CD44 shedding.
Third, anti-CD44 apparently has an impact on chemokine and chemokine receptor expression, which are important parameters in leukocyte migration [64] . Two features, which were modulated by anti-CD44, should be mentioned: First, CCR4 (T cells) [65] , CCR6 (DC and T cells) [66] , and CCR8 (monocytes) [67] expression was unaltered in SkIL but was increased in LN cells of anti-CD44-treated AA/DTH mice. Thus, it becomes likely that in AA/DTH mice, anti-CD44 hampered leukocyte egress. The mechanism and the selective circumstances, which promote retention only in allergen-treated AA mice, remain to be explored. Second, chemokine expression is particularly high in the dermis of allergen-treated mice and anti-CD44; mostly, anti-CD44v10 affected chemokine expression in the dermis rather than in LN cells or SkIL. Taking into account the quite selective interference of anti-CD44v10 with CCL1, CCL17, and OPN expression, we hypothesize that as outlined above, CD44v10 might function as a direct ligand for some chemokines or might bind to a ligand, which triggers selected chemokine expression. These alternative possibilities are currently explored for the CD44v10-OPN interaction.
Taken together, although functional activity of CD44 as a chemokine receptor may well-contribute to a blockade of leukocyte migration by anti-CD44, the observed effects were minor and do not support a decisive/exclusive role of altered chemokine and their receptor expression.
Finally, CD44-integrin associations are obviously of major importance in the CD44-mediated blockade of leukocyte migration. Depending on its activation state, CD44 associates with CD49d, which supports firm adhesion [29] , lymphocyte migration, activation, and apoptosis resistance, which is a result of molecules gaining access to linker and signal-transducing molecules associated with the partner. These features were elaborated with freshly harvested lymphocytes of AA mice [40] and accordingly, are of in vivo relevance. Thus, we asked whether depending on the underlying disease and the preferentially activated leukocyte subpopulation, CD44 may associate with additional integrins and whether these associations are of functional relevance.
In fact, CD44 does not only associate with CD49d but also associates with CD11a, CD11b, and CD54. The integrin associations are only observed in diseased mice; the CD54 association is strengthened in diseased mice. It is notable too that CD44v10 only associated with CD11b and weakly with CD11a in AA/DTH mice. The CD44-integrin/ICAM associations have functional consequences: Anti-CD11a, CD11b, CD49d, and CD54 were only inhibitory when the molecules coimmunoprecipitated with CD44. Also, anti-CD11b inhibited mostly monocyte, and anti-CD49d inhibited mostly activated T cell migration. Migrating leukocytes develop a polarized phenotype, where CD44 relocalizes in the uropod of the cell [68 -70] , and Ets-related molecule proteins associate with [71, 72] and link CD44 to the actin cytoskeleton [73, 74] , a process that involves the small GTPase Rac [75] . These studies did not take into account the association of CD44 with integrins. According to our studies, which demonstrated that by their association, CD44 and CD49d gain access to the partners, signal-transduction molecules [40] , we consider it most likely that anti-CD44 prevents acquisition of the migratory phenotype by interrupting the association with and signal transduction by selected integrins and/or ICAMs.
We demonstrate for the first time that the involvement of CD44 in leukocyte extravasation varies depending on the CD44 isoform, the leukocyte subpopulation, and the organ environment. Anti-CD44, particularly anti-CD44v10, strik-ingly inhibits monocytes and T cells homing into the skin. Anti-panCD44 also interferes with LN homing of T cells. Mechanistically, our data argue against a direct blockade of HA binding by IM7 and K926 but point toward a distorted crosstalk between CD44 and integrins/CAMs, which could well-prohibit the acquisition of a migratory phenotype. In view of our intention to elaborate whether a CD44 blockade could provide an additive therapeutic in allergen-treated, AA-affected individuals, we consider a blockade of CD49d-associated CD44 on effector T cells via a bispecific antibody as most promising, as such a therapy should not interfere severely with the recruitment of DTH effector cells and their therapeutic potential. The feasibility of a selective CD44 targeting via bispecific antibodies has been demonstrated already for a B cell leukemia [61] .
